Detection of Acid Sphingomyelinase/Ceramide Pathway Activation in Radiotherapy Patients Using Intravoxel Incoherent Motion (IVIM) Diffusion-weighted Magnetic Resonance Imaging and Serum Biomarkers
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | June 2015 |
| Contact: | Hebert A. Vargas, MD |
| Phone: | 212-639-4017 |
The purpose of this study is to find out if special blood tests and imaging scans can help
evaluate the effects of the radiation the patient receives as part of standard treatment.
The patient will undergo either stereotactic or conventional radiation treatment as
determined by the treating doctor. Previous evidence suggests that blood flow to tumors is
affected by the amount (dose) of radiation that it receives. This effect may be seen as soon
as 1-2 hours after the radiation is given. This study will evaluate if these changes can be
seen and measured by performing a special type of scan called Intravoxel Incoherent Motion
(IVIM) diffusion-weighted Magnetic Resonance Imaging (MRI) and a blood test. IVIM MRI is a
research exam which is similar to a standard MRI exam, with only a slight difference in the
technical parameters used to acquire the images.
evaluate the effects of the radiation the patient receives as part of standard treatment.
The patient will undergo either stereotactic or conventional radiation treatment as
determined by the treating doctor. Previous evidence suggests that blood flow to tumors is
affected by the amount (dose) of radiation that it receives. This effect may be seen as soon
as 1-2 hours after the radiation is given. This study will evaluate if these changes can be
seen and measured by performing a special type of scan called Intravoxel Incoherent Motion
(IVIM) diffusion-weighted Magnetic Resonance Imaging (MRI) and a blood test. IVIM MRI is a
research exam which is similar to a standard MRI exam, with only a slight difference in the
technical parameters used to acquire the images.
Inclusion Criteria:
- Histologically proven cancer
- Patients deemed clinically appropriate for radiation treatment as part of the
standard care provided by their treating physician, and will receive either 24 Gy
(one fraction) or 3 Gy x 10 fractions.
- Life expectancy > 6 months
- KPS>60%
- Age ≥ 18 years old.
Exclusion Criteria:
- Pregnant patients
- Patients who are unwilling or unable to undergo MRI including patients with
contraindications to MRI such as the presence of cardiac pacemakers or non-compatible
intracranial vascular clips, claustrophobia, inability to lie flat for the duration
of the study etc
- Prior radiotherapy to the site of intended treatment
- Patients with tumor involving brain or spinal cord
- Platelet count <75,000/μl, HgB level <9 g/dl, WBC <3500/μl
- Presence of metastases in the upper thoracic spine (in order to avoid DW- MRI
parameter measurement variability due to cardiac motion)
- Lesions <1.5 cm (to assure robust measurements)
- Non-English speaking patients
We found this trial at
1
site
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Phone: 212-639-4017
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
